Immune System
|
Innovative antibodies against antibiotic-resistant Pseudomonas aeruginosa bacteria
Funding line:
Translational Research
Identification and production of highly neutralizing monoclonal antibodies (mAbs) against multidrug-resistant Pseudomonas aeruginosa. Patient-derived B cells and their anti-PcrV mAbs effectively neutralize bacterial toxicity.
(© Simonis et al., 2023. published in Cell, DOI: 10.1016/j.cell.2023.10.002)
Researchers at the University Hospital of Cologne have identified promising, fully human antibodies that specifically neutralize a central virulence factor of the multidrug-resistant bacterium Pseudomonas aeruginosa. This bacterium causes severe infections, particularly in immunocompromised and ventilated patients. The antibodies are directed against the type III secretion system of the pathogen and show significantly higher efficacy in preclinical models than previously available approaches. The aim of the project is to further develop these antibodies into a novel, targeted therapy for the treatment and prophylaxis of antibiotic-resistant infections.
Further information here.
Dr. Alexandra Albus and Dr. Annalena Wille from the Laboratory for Translational Infection Immunology at University Hospital Cologne examine a culture plate with Pseudomonas aeruginosa in the laboratory.
(© Universität zu Köln, MedizinFotoKöln (MFK)/ Christian Wittke)
